Sargent Investment Group’s Novavax NVAX Stock Holding History

Sargent Investment Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,000	Closed	-$6K	–	216
2021 Q2	$6K	Hold	1,000	–	–	﹤0.01%	208
2021 Q1	$18K	Buy	+1,000	New	+$199K	﹤0.01%	194

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sargent Investment Group's NVAX Position: Q1 2025 in Review

Sargent Investment Group sold out of Novavax (NVAX) in Q1 2025, closing a stake of 50,775 shares — an estimated $437K sold.

Sargent Investment Group first reported a position in NVAX in Q4 2018 and held it in 23 quarters. The position peaked at $4.38M in Q2 2021. 246 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

Sargent Investment Group reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
Sargent Investment Group sold 50,775 Novavax shares in Q1 2025, an estimated $437K.
Sargent Investment Group first reported a position in Novavax in Q4 2018 and held it in 23 quarters.
Sargent Investment Group's Novavax position peaked at $4.38M in Q2 2021.
246 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Sargent Investment Group's 13F filing for Q1 2025, filed 5 May 2025.